Thr1572
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr1572  -  LRP6 (human)

Site Information
EPVPPPPtPRsQyLs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3802448
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 9 , 11 ) , mutation of modification site ( 8 ) , phospho-antibody ( 1 , 8 ) , western blotting ( 1 , 8 )
Disease tissue studied:
chondrosarcoma ( 8 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 3 , 4 , 5 , 6 , 7 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 7 ) , non-small cell large cell lung carcinoma ( 4 ) , small-cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 8 ) , A549 (pulmonary) ( 3 ) , Cal-12T (pulmonary) ( 6 ) , Calu-3 (pulmonary) ( 5 ) , colon ( 1 ) , DLD1 (intestinal) ( 1 ) , DMS53 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 5 ) , HeLa (cervical) ( 11 ) , HT-29 (intestinal) ( 1 ) , IEC-6 (epithelial) ( 1 ) , Jurkat (T lymphocyte) ( 9 ) , lung ( 2 , 3 , 4 , 5 , 6 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 6 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2228 (pulmonary) ( 7 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2405 (pulmonary) ( 6 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H446 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H526 (pulmonary) ( 2 ) , NCI-H69 (pulmonary) ( 2 ) , NCI-H82 (pulmonary) ( 2 ) , RCS (chondrocyte) ( 8 )

Upstream Regulation
Regulatory protein:
BRAF (human) ( 1 ) , FGFR2 (human) ( 8 ) , FGFR3 (human) ( 8 ) , KRas (human) ( 1 )
Putative in vivo kinases:
ERK1 (human) ( 1 , 8 )
Kinases, in vitro:
CK1A (human) ( 10 ) , GSK3A (human) ( 10 )
Treatments:
4-HT ( 1 ) , FGF2 ( 8 ) , PD184352 ( 1 ) , SB216763 ( 1 ) , SCH772984 ( 1 ) , SP600125 ( 1 ) , SU5402 ( 8 ) , U0126 ( 1 , 8 )

Downstream Regulation
Effects of modification on LRP6:
activity, induced ( 1 , 10 ) , molecular association, regulation ( 10 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 , 8 , 10 ) , transcription, induced ( 1 )
Induce interaction with:
axin 1 (human) ( 10 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal carcinoma ( 1 )

References 

1

Lemieux E, et al. (2015) Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914-27
25500543   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

8

Krejci P, et al. (2012) Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation. PLoS One 7, e35826
22558232   Curated Info

9

Guo A (2011) CST Curation Set: 12061; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

10

Macdonald BT, Semenov MV, Huang H, He X (2011) Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6. PLoS One 6, e23537
21887268   Curated Info

11

Moritz A (2008) CST Curation Set: 5067; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.